MK-7762 Safety and Tolerability Study
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, MK-7762 (TBD09), on healthy volunteers to see if it is safe and how it is processed by the body. Researchers will also check if food affects how the drug is absorbed.
Will I have to stop taking my current medications?
Yes, you will need to stop taking any prescription or over-the-counter medications, vitamins, dietary supplements, or herbal products at least 14 days before the trial starts.
Who Is on the Research Team?
Gates MRI
Principal Investigator
Gates MRI
Are You a Good Fit for This Trial?
Healthy adults aged 19-55, non-smokers for at least 6 months, with a BMI of 18-32 and weight over 50 kg. Participants must have normal vital signs, no history of significant diseases or drug abuse, not be on certain medications or supplements recently, and women must be non-childbearing. Men engaging in sexual activity with women who can bear children must agree to use condoms.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Single Ascending Dose (SAD)
Participants receive single ascending doses of MK-7762 to evaluate safety, tolerability, and pharmacokinetics
Multiple Ascending Dose (MAD)
Participants receive multiple ascending doses of MK-7762 over 28 days to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MK-7762 (TBD09)
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bill & Melinda Gates Medical Research Institute
Lead Sponsor
Gates Medical Research Institute
Lead Sponsor
Merck Sharp & Dohme LLC
Industry Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University